Nephros, Inc.NEPHNASDAQ
Loading
Year-over-year SG&A expense growth
3Y CAGR
+15.6%/yr
vs -52.0%/yr prior
Acceleration
+67.6pp
Accelerating
Percentile
P62
Within normal range
vs 3Y Ago
1.5x
Solid growth
Streak
2 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 3.90% |
| Q3 2025 | 1.27% |
| Q2 2025 | -2.35% |
| Q1 2025 | 20.41% |
| Q4 2024 | 8.77% |
| Q3 2024 | -11.33% |
| Q2 2024 | -9.38% |
| Q1 2024 | -11.16% |
| Q4 2023 | 12.82% |
| Q3 2023 | -4.08% |
| Q2 2023 | 4.90% |
| Q1 2023 | 18.86% |
| Q4 2022 | 2.52% |
| Q3 2022 | -7.53% |
| Q2 2022 | -13.41% |
| Q1 2022 | 10.79% |
| Q4 2021 | 14.38% |
| Q3 2021 | -7.34% |
| Q2 2021 | -7.25% |
| Q1 2021 | 46.77% |
| Q4 2020 | -11.79% |
| Q3 2020 | -4.10% |
| Q2 2020 | -17.44% |
| Q1 2020 | 36.75% |
| Q4 2019 | -20.20% |
| Q3 2019 | 27.37% |
| Q2 2019 | -6.65% |
| Q1 2019 | 37.01% |
| Q4 2018 | 2.62% |
| Q3 2018 | -2.02% |
| Q2 2018 | -13.41% |
| Q1 2018 | 41.10% |
| Q4 2017 | 18.59% |
| Q3 2017 | -14.43% |
| Q2 2017 | 14.29% |
| Q1 2017 | 24.19% |
| Q4 2016 | -4.91% |
| Q3 2016 | -18.91% |
| Q2 2016 | 3.47% |
| Q1 2016 | -12.89% |